Using MSNs as the carriers, siRNAs designed to knock down HER2 and an anti-HER2 antibody were then loaded onto MSNs to realize selective delivery of siRNAs into HER2-positive breast cancer cells rather than HER2-negative cells [65]. This evidence concerns the gene ERBB2 and breast carcinoma.